Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma

Archives of Dermatology

Volumn 137, Issue 5, 2001, Pages 581-593

  Duvic, Madeleine ^a   Martin, Ann G ^b   Kim, Youn ^c   Olsen, Elise ^d   Wood, Gary S ^e   Crowley, Constance A ^f   Yocum, Richard C ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; LIGAND; RETINOID X RECEPTOR; REXINOID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICARCINOGENIC AGENTS; CAPSULES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RETREATMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 0034999546     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol. 1999;26:276-289.
2. Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83:534-552.
3. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240-1244.
4. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). Am J Surg Pathol. 1994;18:645-667.
5. Ming M, LeBoit PE. Can dermatopathologists reliably make the diagnosis of mycosis fungoides? if not, who can? Arch Dermatol. 2000;136:543-546.
6. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood. 1996;88;2385-2409
7. Haynes BF, Metzgar RS, Minna JD, Bunn PA. Phenotypic characterization of cutaneous T-cell lymphoma. N Engl J Med. 1981;304:1319-1323.
8. + tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T lymphocyte phenotype. J Cutan Pathol. 1994;21:151-156.
9. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol. 1996;107:392-397.
10. Asudullah K, Friedrich M, Docke WD, Jahn S, Volk HD, Sterry W. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol. 1997;108:743-747.
11. Tan RSH, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides: a disease of antigen persistence. Br J Dermatol. 1974;91:607-616.
12. Safai B, Myskowski PL, Dupont B, et al. Association of HLA-DR5 with mycosis fungoides. J Invest Dermatol. 1983;80:395-397.
13. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107:373-376.
14. Jackow CM, Gather JC, Hearne V, Asano A, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphyloccccus aureus, and oligoclonal T-cell receptor Vb gene expansion. Blood. 1997;89:32-40.
15. Tokura Y, Heald PW, Yan SL, Edelson RL. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol. 1992; 98:33-37.
16. Abrams JT, Vonderheid EC, Kolbe S, Appelt DM, Arking EJ, Balin BJ. Sézary T-cell activating factor is a chlamydia pneumoniae-associated protein. Clin Diagn Lab Immunol. 1999;6:895-905.
17. Grossman D, Rapini RP, Osborne B, Duvic M. Emergence of leprosy in a patient with mycosis fungoides. J Am Acad Dermatol. 1993;30:313-315.
18. Pancake BA, Zucker-Franklin D, Coutavas EE. The cutaneous T-cell lymphoma, mycosis fungoides, is a human T-cell lymphotrophic virus-associated disease. J Clin Invest. 1995;95:547-554.
19. Duvic M, Moore D, Menter A, Vonderheid EC. Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol. 1995;32:939-942.
20. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415-7419.
21. Dreno B, Celerier P, Fleischmann M, Bureau B, Litoux P. Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome. Acta Derm Venereol. 1994;74:355-377.
22. + lymphocytes: an explanation for the epidermotrapism of cutaneous T-cell lymphonna. Blood. 1995;86:651-658.
23. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine TH2 cells. J Invest Dermatol. 1992;99:90-94.
24. Bunn P, Huberman M, Whang-Peng J, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Ann Intern Med. 1980;93:223-230.
25. Foss FA, Sausville EA. Prognosis and staging of CTCL. Hematol Oncol Clin North Am. 1995;9:1011-1019.
26. Zackheim HS, Amin S, Kashani-Sabet M, McMillen A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999;40:418-425.
27. van Doom R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136:504-510.
28. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131:1003-1008.
29. Diamandidou E, Colombe-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150-1159.
30. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135:26-32.
31. Kaye FJ, Bunn PA, Steinberg MS, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784-1790.
32. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999; 43:951-958.
33. Sinha AA, Heald P. Advances in the management of cutaneous T-cell Lymphoma. Dermatol Clin. 1998;16:301-311.
34. Duvic M, Cather JC. Emerging therapies in CTCL. Clin Dermatol 2000;18:147-156.
35. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134:949-954.
36. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;34:1022-1029.
37. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med. 1994;121:592-602.
38. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. JAMA. 1992;267:1354-1358.
39. Edelson RL, Berger CL, Gasparro FP, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med. 1987;316:287-303.
40. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388.
41. 389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998;39:63-73.
42. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol/Oncol Clin North Am. 1995;9:1089-1107.
43. Zackheim HS. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther. 1998;7:15-20.
44. Dreno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol. 1991;125:456-459.
45. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92: 3578-3581.
46. Chambon P. The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog Horm Res. 1995;50:317-332.
47. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem. 1995;270: 923-927.
48. Elder JT, Fisher GJ, Zhang Q-Y, et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol. 1991;96:425-433.
49. Mangelsdorf DJ, Borgmeyer U, Heyman RA, et al. Characterization of the three RXR genes that mediate the action of 9-cis-retinoic acid. Genes Dev. 1992;6: 329-344.
50. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone, and vitamin D3 signalling. Nature. 1992;355:445-449.
51. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-774.
52. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem. 1994;37: 2930-2941.
53. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol. 1997;15:790-795.
54. Rizvi NA, Marshall JL, Dahut W, et al. A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res. 1999;5:1658-1664.
55. Warrell RPJ, Coonley CJ, Kempin SJ, Myskowski P, Safai B, Itri LM. Isotretinoin in cutaneous T-cell lymphoma [letter]. Lancet. 1983;2:629.
56. Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L. 13-cis-retinoic acid effective in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1984;64:563-566.
57. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate - a study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987;67:232-236.
58. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL. Isotretinoin and cutaneous T-cell lymphoma (mycosisfungoides). Arch Dermatol. 1987; 123:201-204.
59. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987;147:529-531.
60. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J Chron Dis. 1981;34:585-597.
61. Food and Drug Administration COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, Md: Food and Drug Administration; 1995, Publication FDA/CDER-95/24.
62. Weinstock M, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer. 1999;85:208-212.
63. 389-interleukin 2 (Ontak) in the management of cutaneous T-cell lymphoma. Curr Pract Med. 1999;2:7-9.
64. Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II. Cancer. 1983;52:2300-2307.
65. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340:1075-1079.
66. Zackheim HS. Treatment of cutaneous T-cell lymphoma. Semin Dermatol. 1994; 13:207-215.
67. Rook AH. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94:902-908.
68. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. In press.
69. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991; 324:1385-1393.
70. Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors (RXR) induces apoptosis in HL-60 cell lines. Mol Cell Biol. 1995;15:3540-3551.
71. Cooke TA, Shalinsky DR, Gottardis MM, Heyman RA, Lampn WW. Regulation of retinoic acid receptor expression by retinoids in human head and neck squamous cell carcinoma (HNSCC) xenograft tumors in athymic mice [abstract]. Proc Annu Meet Am Assoc Cancer Res. 1995;36:A3060.
72. Canan Koch SS, Dardashti LJ, Cesario RM, et al. Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J Med Chem. 1999;42:742-750.
73. Zachanae H, Grunnet E, Thestrup-Pederson K, et al. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor in mycosis fungoides. Acta Derm Venereol. 1982;62:162-164.
74. Kessler JF, Meyskens FLJ, Lovine N, Lynch PJ, Jones SE. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983; 1:1345-1347.
75. Fitzpatrick JE, Mellette JR. Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol. 1986;12:626-629.
76. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage: a report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1989;69:536-538.
77. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991;24:247-252.
78. Smit J, de Jong E, van Hooijdonk, et al. A multicenter phase II clinical and immunohistochemicai trial of systemic bexarotene (Targretin) in patients with moderate to severe plaque psoriasis [abstract]. J Invest Dermatol. 2000;114:776.
79. Vu-Dac N, Schoonjans K, Kosykh V, et al. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996;16:3350-3360.
80. Vu-Dac N, Gervois P, Torra IP, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: contribution to the hypertriglyceridemic action of retinoids. J Clin Invest. 1998;102:625-632.
81. Heald P, Van S-L, Edelson R. Profound deficiency in normal circulating T-cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol. 1994;130:198-203.
82. Posner LE, Fossieck BE, Eddy JL, Bunn PA. Septicemic complications of the cutaneous T-cell lymphomas. Am J Med. 1981;71:210-215.